{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:53:35Z","timestamp":1790823215193,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R335R33AI127591"],"award-info":[{"award-number":["R335R33AI127591"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["S10OD28690-01"],"award-info":[{"award-number":["S10OD28690-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bmcl.2024.130003","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T07:20:16Z","timestamp":1730272816000},"page":"130003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Synthesis and biological evaluation of 4,7,9-trisubstituted benzoxazepines as antileishmanial agents"],"prefix":"10.1016","volume":"114","author":[{"given":"Tara Man","family":"Kadayat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Shoeran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared T.","family":"Hammill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Shin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Cholewo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Landfear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kiplin Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.130003_b0005","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis. Accessed on 2024-03-19."},{"key":"10.1016\/j.bmcl.2024.130003_b0010","unstructured":"Centers for Disease Control and Prevention, Leishmaniasis: https:\/\/www.cdc.gov\/dpdx\/leishmaniasis\/index.html. Accessed 2024-9-25."},{"key":"10.1016\/j.bmcl.2024.130003_b0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/qjmed\/hct116","article-title":"Leishmaniasis: clinical syndromes and treatment","volume":"107","author":"Mcgwire","year":"2014","journal-title":"QJM: An Int J Med"},{"key":"10.1016\/j.bmcl.2024.130003_b0020","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis","volume":"100","author":"Sindermann","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.bmcl.2024.130003_b0025","doi-asserted-by":"crossref","first-page":"e000709","DOI":"10.1136\/bmjgh-2018-000709","article-title":"Why miltefosine\u2014a life-saving drug for leishmaniasis\u2014is unavailable to people who need it the most","volume":"3","author":"Sunyoto","year":"2018","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.bmcl.2024.130003_b0030","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/cr500365f","article-title":"Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis","volume":"114","author":"Nagle","year":"2014","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2024.130003_b0035","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijpddr.2018.09.006","article-title":"Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis","volume":"8","author":"Alc\u00e2ntara","year":"2018","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.bmcl.2024.130003_b0040","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1371\/journal.pntd.0000540","article-title":"Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen","volume":"3","author":"Sharlow","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmcl.2024.130003_b0045","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3389\/fmicb.2016.01379","article-title":"\u03b2-Nitrostyrenes as potential anti-leishmanial agents","volume":"7","author":"Shafi","year":"2016","journal-title":"Front Microb"},{"key":"10.1016\/j.bmcl.2024.130003_b0050","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jac\/dku422","article-title":"Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis","volume":"70","author":"Gupta","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2024.130003_b0055","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1021\/acs.jmedchem.7b01581","article-title":"Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy) phenoxy]-6, 7-dihydro-5 H-imidazo [2, 1-b][1, 3] oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis","volume":"61","author":"Thompson","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130003_b0060","article-title":"Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei","volume":"23 4127","author":"Hwang","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.130003_b0065","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1021\/jm301687p","article-title":"Optimization of chloronitrobenzamides (CNBs) as therapeutic leads for human African trypanosomiasis (HAT)","volume":"56","author":"Hwang","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130003_b0070","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1021\/acs.jmedchem.7b00034","article-title":"7-Substituted 2-nitro-5, 6-dihydroimidazo [2, 1-b][1, 3] oxazines: novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis","volume":"60","author":"Thompson","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130003_b0075","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1021\/acs.jmedchem.0c00499","article-title":"Discovery and characterization of clinical candidate LXE408 as a kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases","volume":"63","author":"Nagle","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130003_b0080","doi-asserted-by":"crossref","first-page":"e0006157","DOI":"10.1371\/journal.pntd.0006157","article-title":"Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening","volume":"11","author":"Ortiz","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmcl.2024.130003_b0085","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1021\/acs.jmedchem.5b00567","article-title":"A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques","volume":"58","author":"Fox","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130003_b0090","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1021\/acs.oprd.5b00037","article-title":"Process development and scale-up of a benzoxazepine-containing kinase inhibitor","volume":"19","author":"Naganathan","year":"2015","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmcl.2024.130003_b0095","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1021\/acs.jcim.1c00472","article-title":"Computer-aided design and synthesis of a new class of PEX14 inhibitors: substituted 2, 3, 4, 5-tetrahydrobenzo [F][1, 4] oxazepines as potential new trypanocidal agents","volume":"61","author":"Fino","year":"2021","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmcl.2024.130003_b0100","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1021\/acs.jmedchem.8b00077","article-title":"Lipophilic efficiency as an important metric in drug design","volume":"61","author":"Johnson","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130003_b0105","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1021\/acs.jmedchem.3c00056","article-title":"Optimization of orally bioavailable antileishmanial 2, 4, 5-trisubstituted benzamides","volume":"66","author":"Kim","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130003_b0110","doi-asserted-by":"crossref","first-page":"12152","DOI":"10.1021\/acs.jmedchem.1c00813","article-title":"Amino-substituted 3-aryl-and 3-heteroarylquinolines as potential antileishmanial agents","volume":"64","author":"Hammill","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130003_b0115","doi-asserted-by":"crossref","first-page":"8889","DOI":"10.1021\/acs.jmedchem.6b00774","article-title":"Development of selective CBP\/P300 benzoxazepine bromodomain inhibitors","volume":"59","author":"Popp","year":"2016","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24004050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24004050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:40:24Z","timestamp":1778517624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24004050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"alternative-id":["S0960894X24004050"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.130003","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and biological evaluation of 4,7,9-trisubstituted benzoxazepines as antileishmanial agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.130003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130003"}}